Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension

Respiratory Medicine

Volumn 104, Issue SUPPL. 1, 2010, Pages

  O'Callaghan, Dermot S ^a,b,c   Savale, Laurent ^a,b,c   Jaïs, Xavier ^a,b,c   Natali, Delphine ^a,b,c   Montani, David ^a,b,c   Humbert, Marc ^a,b,c   Simonneau, Gérald ^a,b,c   Sitbon, Olivier ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

Combination therapy; Endothelin receptor antagonists; Phosphodiesterase type 5 inhibitors; Prostacyclin; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HEART RATE; HUMAN; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYPHYLAXIS; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME;

EID: 77953026428     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.03.020     Document Type: Article

References (28)

1. Gaine S. Pulmonary hypertension. JAMA 284 24 (2000) 3160-3168
2. Galiè N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 34 (2009) 1219-1263
3. Humbert M., Sitbon O., and Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351 14 (2004) 1425-1436
4. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., and Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 6 (1994) 409-415
5. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 6 (2000) 425-434
6. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 334 5 (1996) 296-302
7. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 5 (2002) 322-329
8. Barst R.J., McGoon M., McLaughlin V., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 12 (2003) 2119-2125
9. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 9288 (2001) 1119-1123
10. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 12 (2002) 896-903
11. Galie N., Rubin L., Hoeper M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371 9630 (2008) 2093-2100
12. Barst R.J., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin - a receptor antagonist sitaxsentan. J Am Coll Cardiol 47 10 (2006) 2049-2056
13. Galie N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117 23 (2008) 3010-3019
14. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 20 (2005) 2148-2157
15. Galie N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119 22 (2009) 2894-2903
16. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 2 (2005) 244-249
17. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75 4 (1995) 725-748
18. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 3 (2004) 353-359
19. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 11 (2006) 1257-1263
20. Hoeper M.M., Leuchte H., Halank M., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28 4 (2006) 691-694
21. Channick R.N., Olschewski H., Seeger W., Staub T., Voswinckel R., and Rubin L.J. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 48 7 (2006) 1433-1437
22. McLaughlin V., Rubin L., Benza R., et al. TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 177 (2008) A965
23. Simonneau G., Rubin L.J., Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149 8 (2008) 521-530
24. Wilkens H., Guth A., Konig J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 11 (2001) 1218-1222
25. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 7 (2002) 515-522
26. Ghofrani H.A., Rose F., Schermuly R.T., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42 1 (2003) 158-164
27. O'Callaghan D.S., and Gaine S.P. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 28 1 (2007) 169-185
28. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., and Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26 5 (2005) 858-863